Where does Pulse Biosciences, Inc.'s cash flow data come from?

Every line is extracted from Pulse Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Net income	-$72.78M-35.8%	-$53.59M-26.9%	-$42.21M+27.9%	-$58.51M+8.1%
Depreciation and amortization	$410K-9.5%	$453K-4.2%	$473K-24.9%	$630K+41.9%
Stock-based compensation	$21.46M+57.9%	$13.59M+89.2%	$7.18M+38.3%	$5.19M-64.4%
Change in accounts receivable	——	——	$0+100%	-$61K-200%
Change in inventories	$136K—	$0—	$0-100%	$2.65M-54.4%
Change in accounts payable	——	——	——	-$1.34M-209%
Change in accrued liabilities	——	$3.21M—	——	-$1.79M—
Change in other assets	——	$31K—	$0—	$0—
Other working capital changes	——	——	——	——
Amortization of intangible assets	$665K-0.2%	$666K+0.2%	$665K0.0%	$665K-0.2%
Non-cash operating lease expense	$1.15M—	——	——	——
Change in operating lease liabilities	-$1.37M-27.1%	-$1.08M-20.1%	-$896K-15.8%	-$774K-42.8%
Net cash from operating activities	-$54.12M-48.9%	-$36.34M-10.0%	-$33.04M+29.7%	-$47.01M+13.1%
Capital expenditures	$315K+152%	$125K+3.3%	$121K-69.8%	$401K-8.2%
Net cash from investing activities	-$335K-168%	-$125K-3.3%	-$121K+69.8%	-$401K—
Proceeds from issuance of common stock	$2.49M+186%	$871K—	$0—	——
Net cash from financing activities	$17.15M-84.5%	$110.41M+574%	$16.39M-79.5%	$79.96M+26.4%
Net increase (decrease) in cash	-$37.3M-151%	$73.67M—	——	——
Amortization of capitalized software and acquired intangible assets	$665K-0.2%	$666K+0.2%	$665K0.0%	$665K-0.2%
Depreciation	$410K-9.5%	$453K-4.2%	$473K-24.9%	$630K+41.9%
Operating lease liabilities	-$1.37M-27.1%	-$1.08M-20.1%	-$896K-15.8%	-$774K-42.8%
Increase (Decrease) in Prepaid Expense and Other Assets	$912K—	——	——	——
Operating lease right-of-use asset amortization	$1.15M—	——	——	——
Other Noncash Income (Expense)	——	——	——	——
Payments Of Stock Issuance Costs	$0—	——	——	——
Proceeds from issuance of common stock relating to employee stock plans	——	——	$395K-18.7%	$486K—
Proceeds From Warrant Exercises	$14.11M-71.4%	$49.42M—	——	$26K—
Accrued payables for capital expenditures	——	——	——	——
Increase Decrease In Operating Lease Liability	-$1.37M-27.1%	-$1.08M-20.1%	-$896K-15.8%	-$774K-42.8%
Leased assets obtained in exchange for operating lease liabilities	$0-100%	$830K—	$0—	——
Unpaid Stock Issuance Costs	——	——	——	——
Unpaid Warrant Issuance Costs	——	$13K—	——	——
Write Off Of Deferred Debt Issuance Cost	——	——	——	——
Free cash flow	-$54.44M-49.3%	-$36.47M-10.0%	-$33.16M+30.1%	-$47.41M+13.1%
Free cash flow	-$54.44M-49.3%	-$36.47M-10.0%	-$33.16M+30.1%	-$47.41M+13.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Pulse Biosciences, Inc.'s cash flow data come from?: Every line is extracted from Pulse Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.